Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program

Core Viewpoint - Neurocrine Biosciences has authorized a new share repurchase program allowing for the repurchase of up to $500 million of its shares, in addition to a previously announced $300 million accelerated repurchase program that was completed in early February 2025 [1][2]. Group 1: Share Repurchase Program - The new share repurchase program reflects the company's balanced approach to capital allocation, which includes investing in commercial products and returning capital to shareholders [2]. - Repurchases under the new authorization may occur at management's discretion through various methods, including open-market transactions and privately negotiated transactions [2]. Group 2: Company Overview - Neurocrine Biosciences is a biopharmaceutical company focused on neuroscience, dedicated to developing treatments for neuropsychiatric, neurological, and neuroendocrine disorders [3]. - The company has a diverse portfolio that includes FDA-approved treatments for conditions such as tardive dyskinesia and Huntington's disease, along with a robust pipeline of compounds in mid- to late-phase clinical development [3].